#United States #NASDAQ #Boulder #Muscle Disease #Edgewise

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Boulder, Colorado - December 2, 2025 - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a pioneering biopharmaceutical company focused on muscle diseases, has announced the granting of inducement stock options for a newly hired non-executive employee. This grant consists of 26,250 shares of common stock and is aligned with Edgewise's 2024 Inducement Equity Incentive Plan.

The exercise price for these stock options is set at $26.04 per share, reflecting the closing stock price on the grant date. Vesting for the incentives is structured such that 25% of the shares will be accessible on the one-year anniversary of the employee's start date. Subsequently, 1/48th of the total options will vest every month, contingent on the employee's continued service.

This grant is made under the provisions of Nasdaq Listing Rule 5635(c)(4), which permits inducements to attract talent in the biopharmaceutical space. As a company committed to addressing the challenges of muscular dystrophies and severe cardiac conditions, Edgewise recognizes the importance of incentivizing new talent for its mission.

About Edgewise Therapeutics

Edgewise Therapeutics is a front-runner in developing groundbreaking therapeutics targeting muscle pathologies. The company's expertise in muscle physiology fosters advancements in treatment options. Currently, Edgewise is in late-stage clinical trials for Sevasemten, a first-in-class fast skeletal myosin inhibitor, addressing Becker and Duchenne muscular dystrophies. Alongside this, EDG-7500 is under development for hypertrophic cardiomyopathy, while EDG-15400 aims to treat heart failure.

The core mission of Edgewise Therapeutics is to transform the lives of individuals and families grappling with debilitating muscle disorders. For more information on their innovative products and ongoing research, visit their official website at www.edgewisetx.com or connect with them on social media platforms like LinkedIn, Twitter, Facebook, and Instagram.

Conclusion

The inducement granted to the new employee underscores Edgewise’s commitment to expanding its talented workforce, which is essential for the company’s growth and the continual development of life-altering treatments for patients suffering from severe muscle conditions. By investing in human capital in this way, Edgewise Therapeutics positions itself strategically within the biopharmaceutical industry, guaranteeing that it remains at the forefront of innovation.